DNA · Ginkgo Bioworks Holdings, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $19.47M | - | $38.84M | $49.60M | $48.32M | - | $89.05M | $56.21M | $37.94M | - |
| Cost of Revenue | $4.09M | - | - | - | - | - | - | - | - | - |
| Gross Profit | $15.38M | - | - | - | - | - | - | - | - | - |
| R&D | $49.92M | - | $69.35M | $53.37M | $70.92M | - | $77.01M | $134.22M | $136.46M | - |
| SG&A | $37.83M | - | $44.95M | $43.28M | $49.04M | - | $52.29M | $66.28M | $70.29M | - |
| Total Operating Expenses | $90.85M | - | $128.85M | $115.14M | $137.29M | - | $144.25M | $279.15M | $215.95M | - |
| D&A | $12.80M | - | - | - | $15.37M | - | - | - | $12.87M | - |
| Operating Income | ($71.37M) | - | ($90.02M) | ($65.54M) | ($88.97M) | - | ($55.20M) | ($222.94M) | ($178.00M) | - |
| Interest Expense | - | - | - | - | - | - | ($15.02M) | ($14.35M) | - | - |
| Income Tax | ($80.0K) | - | $1.0K | ($283.0K) | $88.0K | - | ($375.0K) | $190.0K | $31.0K | - |
| Net Income | ($90.96M) | - | ($80.75M) | ($217.18M) | ($90.96M) | - | ($56.40M) | ($217.18M) | ($165.91M) | - |
| EPS - Basic | ($1.39) | - | ($1.45) | ($1.10) | ($1.68) | - | ($1.08) | ($4.40) | ($3.20) | - |
| EPS - Diluted | - | - | ($1.45) | ($1.10) | ($1.68) | - | ($1.08) | ($4.40) | ($3.20) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $143.86M | $167.20M | $111.06M | $203.57M | $312.42M | $561.57M | $616.21M | $730.37M | $840.44M | $944.07M |
| Accounts Receivable | $19.82M | $24.03M | $21.43M | $22.15M | $26.29M | $21.86M | $23.41M | $18.59M | $24.19M | $17.16M |
| Inventory | - | - | - | - | - | - | - | - | - | $46.0K |
| Accounts Payable | $16.31M | $10.57M | $10.70M | $11.20M | $11.27M | $14.17M | $15.70M | $23.03M | $27.00M | $9.32M |
| Current Assets | $409.95M | $471.84M | $506.08M | $523.02M | $564.53M | $602.74M | $662.48M | $783.36M | $903.02M | $1.00B |
| Total Assets | $1.03B | $1.12B | $1.19B | $1.23B | $1.29B | $1.38B | $1.48B | $1.63B | $1.58B | $1.67B |
| Current Liabilities | $79.59M | $95.97M | $115.28M | $96.72M | $115.67M | $107.27M | $114.43M | $166.15M | $169.04M | $163.86M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $589.92M | $611.11M | $629.38M | $618.06M | $646.04M | $661.39M | $682.94M | $792.18M | $594.49M | $568.19M |
| Stockholders' Equity | $443.15M | $508.59M | $612.95M | $612.95M | $647.43M | $716.06M | $797.94M | $833.07M | $987.27M | $1.10B |
| Retained Earnings | ($6.23B) | ($6.15B) | ($6.07B) | ($5.99B) | ($5.93B) | ($5.84B) | ($5.73B) | ($5.67B) | ($5.46B) | ($5.29B) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ($46.69M) | - | - | - | ($51.52M) | - | - | - | ($89.26M) | - |
| Investing Cash Flow | $23.13M | - | - | - | ($198.68M) | - | - | - | ($12.11M) | - |
| Financing Cash Flow | ($19.0K) | - | - | - | ($207.0K) | - | - | - | ($845.0K) | - |
| CapEx | $1.93M | - | - | - | $7.62M | - | - | - | $6.71M | - |
| Free Cash Flow | ($48.62M) | - | - | - | ($59.14M) | - | - | - | ($95.97M) | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | 79.0% | - | - | - | - | - | - | - | - | - |
| Operating margin | -366.5% | - | -231.8% | -132.1% | -184.1% | - | -62.0% | -396.7% | -469.1% | - |
| EBITDA margin | -300.8% | - | - | - | -152.3% | - | - | - | -435.2% | - |
| Net margin | -467.1% | - | -207.9% | -437.8% | -188.2% | - | -63.3% | -386.4% | -437.3% | - |
| Free cash flow margin | -249.7% | - | - | - | -122.4% | - | - | - | -252.9% | - |
| FCF / Net income | 0.53 | - | - | - | 0.65 | - | - | - | 0.58 | - |
| R&D / Revenue | 256.3% | - | 178.6% | 107.6% | 146.8% | - | 86.5% | 238.8% | 359.6% | - |
| SG&A / Revenue | 194.3% | - | 115.8% | 87.2% | 101.5% | - | 58.7% | 117.9% | 185.2% | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -8.8% | - | -6.8% | -17.6% | -7.0% | - | -3.8% | -13.4% | -10.5% | - |
| Return on equity | -20.5% | - | -13.2% | -35.4% | -14.0% | - | -7.1% | -26.1% | -16.8% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 5.15 | 4.92 | 4.39 | 5.41 | 4.88 | 5.62 | 5.79 | 4.71 | 5.34 | 6.11 |
| Quick ratio | 5.15 | 4.92 | 4.39 | 5.41 | 4.88 | 5.62 | 5.79 | 4.71 | 5.34 | 6.11 |
| Cash ratio | 1.81 | 1.74 | 0.96 | 2.10 | 2.70 | 5.24 | 5.39 | 4.40 | 4.97 | 5.76 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | 3.7x | 15.5x | - | - |
| Equity multiplier | 2.33 | 2.20 | 1.94 | 2.01 | 2.00 | 1.92 | 1.86 | 1.95 | 1.60 | 1.52 |
| Liabilities / Assets | 0.57 | 0.55 | 0.53 | 0.50 | 0.50 | 0.48 | 0.46 | 0.49 | 0.38 | 0.34 |
| Efficiency | ||||||||||
| Asset turnover | 0.02 | - | 0.03 | 0.04 | 0.04 | - | 0.06 | 0.03 | 0.02 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | 371d | - | 201d | 163d | 199d | - | 96d | 121d | 233d | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | 1455d | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | - | - | 1.3x | 1.0x | 0.5x | - | 0.5x | 33.0x | 94.2x | - |
| P / S | - | - | 20.9x | 12.4x | 6.4x | - | 4.8x | 488.5x | 2452.2x | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | -59.7% | - | -56.4% | -11.7% | 27.3% | - | 60.6% | -30.2% | -53.0% | - |
| Revenue CAGR (3y) | -37.7% | - | -16.4% | 4.4% | -34.0% | - | 88.5% | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 19.8% | - | -63.1% | 70.6% | 50.0% | - | 80.7% | -21.1% | 17.5% | - |
| Net income growth (YoY) | 0.0% | - | -43.2% | 0.0% | 45.2% | - | 81.4% | -25.3% | 19.1% | - |
| EPS growth (YoY) | - | - | -34.3% | 75.0% | 47.5% | - | -575.0% | -4788.9% | -2809.1% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | 17.8% | - | - | - | 38.4% | - | - | - | 12.8% | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -31.6% | -29.0% | -23.2% | -26.4% | -34.4% | -34.7% | -36.3% | -44.6% | -38.6% | -36.8% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$132.75M totalCell Engineering Segment$132.75M · 100.0%
Product / service
$170.16M totalCell Engineering Revenue$132.75M · 78.0%
Service$37.41M · 22.0%
Peer comparison
Same SIC group: Biological Products, (No Diagnostic Substances)
Comparing Ginkgo Bioworks Holdings against the 5 most active filers in the same SIC group.